Skip to main content

Calidi Biotherapeutics, Inc.

CLDI
Exchange
NYSE
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0001855485

No open-market purchases or sales by Calidi Biotherapeutics, Inc. insiders were filed in the last 90 days; 23 institutions reported holding it in 13F filings for Q2 2026, worth $89.3K in total; no superinvestor holds it.

Other share classesCLDWW

Q4 2022 vs. Q3 2022

How the institutions holding Calidi Biotherapeutics, Inc. changed between Q3 2022 and Q4 2022.

All holders in Q4 2022All holders in Q3 2022

13F holders of CLDI: Q3 2022 compared with Q4 2022
MeasureQ3 2022Q4 2022Change
Holders2125+4
Shares3.72M3.93M+215.4K (+5.8%)
Value$36.1M$39.6M+$3.49M (+9.7%)

New holders (8)

Institutions that held Calidi Biotherapeutics, Inc. at the end of Q4 2022 but not at the end of Q3 2022.

Institutions new to CLDI in Q4 2022
InstitutionSharesValue% of portfolio
Hudson Bay Capital Management LP500,000$5.08M0.06%
Bank of Montreal316,628$3.22M0.00%
Elequin Capital LP169,700$1.73M0.49%
Cubist Systematic Strategies, LLC95,510$971.3K0.01%
PenderFund Capital Management Ltd.53,100$731.0K0.22%
Karpus Management, Inc.24,200$246.1K0.01%
Commonwealth of Pennsylvania Public School Empls Retrmt Sys13,400$136.0K0.00%
UBS Group AG24$2440.00%

Sold out (4)

Institutions that held Calidi Biotherapeutics, Inc. at the end of Q3 2022 and filed for Q4 2022 without it.

Institutions that sold out of CLDI in Q4 2022
InstitutionShares, Q3 2022Value, Q3 2022
Logan Stone Capital, LLC149,600$1.47M
Cowen and Company, LLC90,624$893.0K
Wolverine Asset Management LLC17,943$176.0K
Old Mission Capital LLC12,704$125.0K